GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). by Zampetti, Simona et al.
GADA Titer-Related Risk for Organ-Specific
Autoimmunity in LADA Subjects Subdivided
according to Gender (NIRAD Study 6)
Simona Zampetti, Marco Capizzi, Marialuisa Spoletini, Giuseppe Campagna,
Gaetano Leto, Laura Cipolloni, Claudio Tiberti, Emanuele Bosi, Alberto Falorni,
and Raffaella Buzzetti, for the NIRAD Study Group
Department of Internal Medicine and Medical Specialties (S.Z., M.C., M.S., G.C., G.L., L.C., C.T., R.B.),
“Sapienza” University, 00161 Rome, Italy; General Medicine, Diabetes, and Endocrinology (E.B.), San
Raffaele Vita-Salute University, 20132 Milan, Italy; and Department of Internal Medicine (A.F.), University
of Perugia, 06123 Perugia, Italy
Context:Latentautoimmunediabetes inadults (LADA) includesaheterogeneouspopulationwherein,
based on glutamic acid decarboxylase antibody (GADA) titer, different subgroups of subjects can be
identified.
Objective: The aimof thepresent studywas to evaluateGADA titer-related risk for-cell andother
organ-specific autoimmunity in LADA subjects.
Methods:Adult-onsetautoimmunediabetes subjects (n236)andtype2diabetes (T2DM) subjects
(n 450) were characterized for protein tyrosine phosphatase (IA-2IC and IA-2256–760), zinc trans-
porter 8 (ZnT8), thyroidperoxidase, (TPO), steroid 21-hydroxylase (21-OH), tissue transglutaminase
(tTG), and antiparietal cell (APC) antibodies.
Results:High GADA titer compared to lowGADA titer showed a significantly higher prevalence of
IA-2IC, IA-2256–760, ZnT8, TPO, andAPCantibodies (P0.04 for all comparison). 21-OHantibodieswere
detected in 3.4%of highGADA titer. A significant decreasing trendwas observed fromhighGADA to
low GADA and to T2DM subjects for IA-2256–760, ZnT8, TPO, tTG, and APC antibodies (P for trend
0.001). TPOwas the only antibody showing a different prevalence between gender; lowGADA titer
andT2DMfemalepatientshadahigher frequencyofTPOantibodycomparedtomales (P0.0004and
P 0.0006, respectively), where the presence of high GADA titer conferred an odds ratio of 8.6 for
TPO compared to lowGADA titer. After subdividinghigh and lowGADA titer subjects according
to the number of antibodies, we observed that 73.3%of high GADA titer subjects were positive
for at least one or more antibodies, compared to 38.3% of low GADA titer (P  0.0001).
Conclusions: In LADA subjects, high GADA titer was associated with a profile of more severe
autoimmunity and, in male gender, specifically predisposed to thyroid autoimmunity. A regular
screening for other antibodies is recommended in LADA patients according to GADA titer and
gender. (J Clin Endocrinol Metab 97: 3759–3765, 2012)
Latent autoimmune diabetes in adults (LADA), the slowlyprogressive form of autoimmune diabetes, is not one
clear-cut disease entity but includes a heterogeneous popu-
lation wherein, based on glutamic acid decarboxylase anti-
body (GADA) titers, different subgroups of subjects can be
identified (1).
In the Non-Insulin Requiring Autoimmune Diabetes
(NIRAD) Study 1, we demonstrated the presence of two
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different populations among individuals with adult-onset
autoimmune diabetes (2); analysis of GADA titers showed a
bimodal distribution that identified two subgroups of pa-
tients with either a low or a high GADA titer.
The potential for several factors to predict progression
toward insulin dependence has beenpreviously investigated.
However, the only marker that has been widely demon-
strated to correlate with a faster decline of islet function in
LADAwas thepresenceofmultiple-cell-specificantibodies
(3, 4). LADA has also been associated with other autoim-
mune diseases (5, 6). Gambelunghe et al. (7) reported an
ongoing thyroid or adrenal autoimmunity in more than one
fourth of 67GAD65 antibody-positive subjects with a prev-
alence of thyroid peroxidase (TPO) three times higher in fe-
male subjects compared with males. The same female/male
ratio was reported for thyroid autoimmunity (thyroid mi-
crosomal and thyroglobulin antibodies) in Finnish LADA
subjects subdivided into tertiles of GADA positivity (8).
More recently, Jin et al. (9) reported that a high titer of
GADAwasastrongpredictor for thedevelopmentof thyroid
autoimmunity in Chinese patients with type 1 diabetes mel-
litus (T1DM)andLADA.It iswellknownthatorgan-specific
endocrine autoimmunity develops more frequently in
women, including T1DMwith thyroid autoimmunity (10);
the production of TPO antibodies is inheritable in an auto-
somal fashion in women but not in men (11).
Although an association between LADA and other or-
gan-specific autoimmunity has been previously reported,
GADA titer and gender-related risk has not been quanti-
fied so far.
In light of these findings, the aim of the present study
was to estimate, inLADAsubjects, theGADAtiter-related
risk for organ-specific autoimmunity, diabetes, and non-
diabetes-related protein tyrosine phosphatases (IA-2IC
and IA-2256–760), zinc transporter 8 (ZnT8), TPO, steroid
21-hydroxylases (21-OH), tissue transglutaminase (tTG),
and antiparietal cell (APC).
The knowledge of the odds ratio (OR) for organ-spe-
cific antibodies in LADA could be useful to identify pa-
tients in whom to perform the evaluation of these anti-
bodies, in order to estimate the time to insulin dependence
(-cell-specific antibodies) and to diagnose autoimmune
diseases at an early stage (other organ-specific antibodies).
Subjects and Methods
Adult-onset autoimmunediabetic subjects (n236;meanage of
onset, 50.4 12.9 yr) and age- and sex-matched type 2 diabetes
mellitus (T2DM) subjects (n  450; mean age of onset, 51.6 
10.81 yr) were selected from the NIRAD Study cohort of 5330
T2DM subjects (12).
GADAwere measured by a radiobinding assay using in vitro
translated [35S]methionine-labeled GAD65 (13). Results for
GADA were converted into arbitrary units (a.u.) by extrapola-
tion from a standard curve with a local standard designated 100
arbitrary units. The thresholds for positivity were determined
from the 99th centile of control subjects and corresponded to 3
a.u. for GADA. The distribution of GADA titer in patients with
autoimmune diabetes was independent of diabetes duration and
showed a bimodal distribution. Consistent with this observa-
tion, patients with autoimmune diabetes (GADA titer 3 a.u.)
were divided into subgroups representing the two distributions,
identified considering as a cutoff the nadir of the distribution and
namely low (taken to be32 a.u.) or high (taken to be32 a.u.)
GADA titer as extensively explained in our previous study (2).
Samples with low GADA titer were validated for GAD-spe-
cific binding by competition assay with an excess of cold insulin
(2). Based on the Diabetes Antibody Standardization Program
(14) as a reference, the threshold of 32 a.u.was equivalent to 300
World Health Organization units (2).
IA-2IC, IA-2256–760, ZnT8, and tTG antibodies were mea-
sured by previously described radioimmunoprecipitation assays
(15, 16). TPO and APC antibodies were measured using RIA
(Medipan, Berlin, Germany) and ELISA (Axa Diagnostics, Po-
mezia Italy) commercially available kits, respectively. 21-OH
antibodies were analyzed by a radiobinding assay to recombi-
nant human 21-OH radiolabeled with [35S], as previously de-
scribed (17).
Statistical analyses were performed using SPSS software, ver-
sion 18 (SPSS Inc., Chicago, IL). Frequency differences were
compared using the 2 test (with Yates’ continuity correction) or
Fisher’s exact test when appropriate. A P value0.05 was con-
sidered statistically significant.
Results
Table 1 shows the frequency of autoimmune diabetes-spe-
cific antibodies in high GADA titer, low GADA titer,
and T2DM. Subjects with high GADA titer, compared
with low GADA titer, showed a significantly higher
prevalence of IA-2IC, IA-2256–760, and ZnT8 (P  0.04
for all comparisons). Subjects with high GADA titer
compared with T2DM showed a significantly higher
prevalence of IA-2256–760 and ZnT8 (P 0.0001 for all
comparisons). A significant decreasing trend was also
observed from high GADA titer to low GADA titer and
to T2DM subjects for IA-2256–760 and ZnT8 antibodies
(P  0.0001 for all comparisons).
After subdividing LADA patients according to gender,
we did not observe any significant difference in the fre-
quency of the three diabetes-specific antibodies between
male and female patients. A significantly higher frequency
of all antibodies was observed in high GADA titer com-
pared with low GADA titer and T2DM, irrespective of
gender—the high GADA titer conferring the highest OR
for all the three antibodies compared with T2DM. High
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GADA titer males showed anORof 63 for the presence of
ZnT8 antibody.
In Table 2, we reported the prevalence of other organ-
specific antibodies in high GADA titer, low GADA titer,
and T2DM patients. Subjects with high GADA titer com-
paredwith lowGADAtiter subjects showeda significantly
higher prevalence of TPO and APC antibodies (P 0.004
for all comparisons). Subjectswith highGADA titer, com-
pared with T2DM, showed a significantly higher preva-
lence of TPO, tTG, and APC antibodies (P  0.01 for all
comparisons). Antibodies to 21-OH showed a prevalence
of 3.4% (4 of 116) in high GADA titer and were not pres-
ent either in low GADA titer (0 of 120) or in T2DM (0 of
450).
A significant decreasing trend was also observed from
highGADAtiter to lowGADAtiter and toT2DMsubjects
for TPO, tTG, and APC and antibodies (P 0.001 for all
comparisons). Interestingly, the presence of high GADA
titer conferred an OR of 10 for tTG antibody positivity
compared with patients with T2DM.
No different gender distribution was observed in
LADA subjects, subdivided according to GADA titer, for
TABLE 1. Prevalence of autoimmune diabetes-specific autoantibodies in high and low GADA titer and in T2DM
patients
High
GADA titer
Low
GADA titer T2DM
OR
P for trend
High
vs. low GADA
High
vs. T2DM
Low
vs. T2DM
n 116 120 450
No. of males/females 61/55 62/58 234/216
IA-2IC 29 (25) 10 (8.3) 0 3.7 (1.7–7.9)
a nc nc
Male 16 (26.2) 6 (9.7) 0 3.0 (1.1–8.0) nc nc
Female 13 (23.6) 4 (6.9) 0 3.7 (1.1–11.6) nc nc
IA-2256–760 41 (35.3) 18 (15) 13 (2.9) 5.8 (3.1–10.8)
a 18.3 (9.4–35.9)b 5.9 (2.8–12.5)c 0.0001
Male 20 (32.8) 8 (12.9) 7 (2.9) 3.2 (1.3–8.2)a 15.8 (6.2–39.8)b 4.8 (1.6–13.8)c 0.0001
Female 21 (38.2) 10 (17.2) 6 (2.8) 2.9 (1.2–7.0)a 21.6 (8.1–57.4)b 7.2 (2.5–21)c 0.0001
ZnT8 34 (29.3) 10 (8.3) 7 (1.6) 4.6 (2.1–9.8)a 26.2 (11.2–61.2)b 5.7 (2.1–15.4)c 0.0001
Male 13 (21.3) 6 (9.7) 1 (0.4) 2.5 (0.9–7.2) 63 (8.1–494.1)b 23 (2.8–198.4)c
Female 21 (38.2) 4 (6.9) 6 (2.8) 6.4 (2.1–19.3)a 21.6 (8.1–57.4)b 2.6 (0.7–9.5) 0.0001
Data are expressed as number (percentage) or OR (95% confidence interval), unless stated otherwise. IA-2IC  IA-2256–760  ZnT8 in high GADA
titer, n  15 (12.9%); in low GADA titer, n  7 (5.8%). nc, Not calculable.
a For high GADA vs. low GADA, P  0.04.
b For high GADA vs. T2DM, P  0.0001.
c For low GADA vs. T2DM, P  0.004.
TABLE 2. Prevalence of autoantibodies in high and low GADA titer and in T2DM patients
High
GADA titer
Low
GADA titer T2DM
OR
P for trend
High
vs. low GADA
High
vs. T2DM
Low
vs. T2DM
n 116 120 450
No. of males/females 61/55 62/58 234/216
TPO 43 (37.1) 20 (16.6) 47 (10.4) 2.9 (1.6–5.4)a 5.0 (3.1–8.2)b 1.7 (1.0–3.0) 0.0001
Male 21 (34.4) 3 (4.8) 13 (5.5) 8.6 (2.5–29.8)a 8.9 (4.1–19.3)b 0.9 (0.2–3.1) 0.0001
Female 22 (40) 17 (29.3) 34 (15.7) 1.6 (0.7–3.5) 3.6 (1.8–6.8)b 2.0 (1.1–3.7)c 0.0001
21-OH 4 (3.4) 0 0 9.6 (0.5–181.2) nc nc
Male 2 (3.3) 0 0 5.2 (0.2–111.8) nc nc
Female 2 (3.6) 0 0 5.5 (0.2–116.6) nc nc
tTG 5 (4.3) 1 (0.8) 2 (0.4) 5.4 (0.6–46.6) 10 (1.9–52.7)b 1.9 (0.17–20.9) 0.001
Male 1 (1.6) 0 0 3.1 (0.1–77.6) nc nc
Female 4 (7.3) 1 (1.7) 2 (0.9) 4.5 (0.5–41.3) 8.4 (1.5–47.1)b 2.0 (0.2–22.8)
APC 29 (25) 11 (9.1) 49 (10.8) 3.0 (1.6–7.0)a 2.7 (1.6–5.6)b 0.8 (0.4–1.6) 0.0004
Male 13 (21.3) 7 (11.3) 28 (12) 2.0 (0.7–5.3) 2.0 (1.0–4.1) 0.9 (0.9–2.2)
Female 16 (29.1) 4 (6.9) 21 (9.7) 4.6 (1.5–14.3)a 3.3 (1.6–6.5)b 0.7 (0.2–2.1) 0.001
Data are expressed as number (percentage) or OR (95% confidence interval), unless stated otherwise. nc, Not calculable.
a For high GADA vs. low GADA, P  0.004.
b For high GADA vs. T2DM, P  0.01.
c For low GADA vs. T2DM, P  0.03.
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all analyzed antibodies, with the exception of TPO. We
found a higher prevalence of TPO antibodies in low
GADA titer and T2DM female patients compared with
males (P 0.0004 and P 0.0006, respectively; data not
shown). In highGADA titer patients, however, we did not
observe any difference between female and male subjects
for TPO antibody positivity. In females, TPO antibodies
were significantly more frequent both in high and low
GADA titers compared with T2DM. In males, TPO anti-
bodies were significantly more frequent in patients with
highGADA titer comparedwith patients with lowGADA
titer and T2DM. Thus, in male patients, the presence of
high GADA titer conferred an OR of 8.6 for TPO posi-
tivity compared with patients with low GADA titer.
After subdividing high and low GADA titer subjects
according to the number of antibodies, we observed that
73.3% of high GADA titer subjects were positive for at
least one ormore antibodies comparedwith 38.3%of low
GADA titer (P  0.0001) (Table 3).
Discussion
The originality of the present study is due to the charac-
terization of a panel of antibodies directed against differ-
ent diabetes and non-diabetes-related autoantigens, in-
cluding IA-2IC, IA-2256–760, ZnT8, TPO, 21-OH, tTG,
and APC, in LADA patients and in T2DM.
We demonstrated that high GADA titer is associated
with a profile of more severe autoimmunity consisting in
higher prevalence of organ-specific antibodies compared
with low GADA titer and T2DM. This finding not only
confirms but also extensively extends our previous obser-
vations, showing the presence of a higher frequency of
associated thyroid autoimmunity in LADA patients com-
pared with classic T2DM (2, 16).
Although LADA can be considered amajor component
of the organ-specific autoimmune disease group, few data
are available on the risk of these patients for other auto-
immunediseases. Thepresence ofZnT8antibodies in high
GADA titer male patients confers an OR of 63 compared
with T2DM patients. Kawasaki et al. (18) found that
ZnT8, with other diabetes-related antibodies, improves
the prediction of a future insulin deficiency in adult-onset
autoimmune diabetes. A recent study showed that ZnT8
antibody identified a subgroup of subjects at higher risk of
diabetes progression in relatives of patients already posi-
tive foroneantibody (anti-insulinorGAD65or IA-2) (19).
ZnT8 is a highly -cell-specific protein, and its mea-
surement may be useful in monitoring islet destruction
after onset and in evaluating therapeutic interventions
aimed to limit -cell-specific autoreactivity or restore
-cellmass (20). This finding supports the importance and
utility to evaluate ZnT8 antibodies in high GADA titer
male patients because their presence could confer a higher
risk for insulin requirement in LADA patients compared
with low GADA titer.
In the Botnia Study (5) and in a more recent work (9),
LADA patients with high GADA titer showed a higher
frequency of TPO antibodies compared with low GADA
titer. These findings are in line with our results in which
high GADA titer compared with low GADA titer showed
a significantly higher prevalence of TPO antibodies (2).
Van Deutekom et al. (1) reported that the clinical charac-
teristics of LADA patients correlate with the titer and
number of diabetes-associated antibodies and that TPO
and/or 21-OH antibodies are present in more than one
fourth of LADA.
Previous studies performed in T1DM and in LADA (7,
21, 22) showed that the frequency of TPO was higher in
females comparedwithmales, suggesting that female gen-
der could be a predisposition factor to the development of
organ-specific autoimmunity in T1DM. In view of this
consideration, we analyzedwhether in LADApatients the
TPOdistribution, according toGADAtiter,was somehow
influenced by gender bias.
In agreement with a previous study (7), we found a
higher prevalence of TPO antibodies in overall female
LADApatients comparedwithmales. The interesting data
of the present study is that in patients with high GADA
titer, no differences were detected between females and
males for TPO antibody positivity. This observation
should be taken into account considering the previous ev-
idence of the gender bias for T1DM (higher prevalence in
males) (23, 24). In LADA, the gender bias of the autoim-
mune diabetes could influence the gender bias of another
autoantibody according to the level of the immunodom-
inant antibody (GADA titer). This suggests that the auto-
immune background of high GADA titer patients in
LADA could act as “promoter” for specific thyroid
epitope spreading inmale patients. TheORof 8.6 forTPO
antibodies conferred by highGADA titer inmale patients,
comparedwith lowGADA titer, indicates the relevance of
screening for thyroid autoimmunity in the LADA popu-
lation to detect asymptomatic thyroid dysfunction.
TABLE 3. High and low GADA titer patients divided
according to the number of autoantibodies
High GADA titer Low GADA titer
n 116 120
0 Aba 31 (26.7) 74 (61.7)
1–5 Aba 85 (73.3) 46 (38.3)
Data are expressed as number (percentage).
a High GADA titer vs. low GADA titer, P  0.0001.
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In a previous Italian study performed on LADA pa-
tients, 21-OH antibodies were detected in 5% of cases,
compared with 0% in the control group of T2DM pa-
tients (7).
Falorni et al. (6) found that 21-OH antibodies were
detected only in GADA-positive subjects. In agreement
with this study,we also observed a quite high frequency of
21-OH antibodies (3.4%) in GADA-positive subjects. To
our knowledge, this is the first study to assess the preva-
lence of 21-OH antibodies in LADA patients subdivided
according to GADA titer.
Other reports compared the prevalence of tTG anti-
bodies, a sensitive marker of celiac disease, in LADA and
T2DMpatients (25–27).Conflicting findingswere report-
ed; in one study, LADA patients had a higher prevalence
of tTG antibodies compared with T2DM (1), whereas in
another study, the frequency of tTGA was similar in
LADA and in T2DM patients (28).
Overall, our results provide an additional support to
the concept of heterogeneity within autoimmune dia-
betes in adults, indicating that whenGADA titer is high,
the disease is characterized by a profile of more severe
and extended autoimmunity compared with lowGADA
titer.
Nonetheless, considering the frequent finding of low
GADA titer in nondiabetic individuals (29), the possibility
that these antibodies were “assay”-related false-positive
was tested by an inhibition assay with an excess of unla-
beled antigen in all samples available for retesting. Results
showed that in most cases, antibody binding was specific
for GAD (2). Furthermore, the coexistence in most of
LADA with low GADA titer of mild insulin resistance
features with a profile of autoimmunity, although less se-
vere compared with high GADA titer patients (2), tend to
confirm that a significant number of low GADA patients
can be related to a real anti-islet autoimmunity. These
observations, while suggesting that a significant number
of low GADA patients should be real LADA, cannot ex-
clude the possibility that some of these patients could be
“biological” false positive.
Epitope spreading could be one of the possible mech-
anisms for the increased frequency of associated antibod-
ies in high GADA titer patients. A self-directed immune
response induced by a single epitope could spread to in-
clude other epitopes on other self molecules clustered in
close vicinity of the target cell (30). Recent evidence from
animal models of autoimmune diseases points to epitope
spreading as a crucial mechanism in the development of
autoimmunity, relapse, and disease progression (31).
We may speculate that in high GADA titer patients a
“cascade” of epitopes may contribute to the development
of autoimmunity and that the presence of multiple anti-
bodies is a better index of disease progression than the
prevalence of antibodies directed against a single antigen.
In conclusion, our findings show a higher frequency of
organ-specific antibodies in high GADA titer subjects,
confirming the high intensity of the autoimmune process.
Furthermore, considering that the risk for other specific
antibodies in LADA vary according to GADA titer and
gender, knowing the specific OR could help clinicians to
perform their screening.
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